Case Study

The challenge

Rapidly scaling a genomic research initiative with results that can be integrated into clinical care for a large population in Nevada.

As part of the expansion of the Healthy Nevada Project (HNP), Renown Health Institute for Health Innovation (Renown IHI) sought to engage 40,000 Nevadans in a large scale genomics research initiative that would drive novel discoveries as well as improve clinical care.

This meant that, in addition to needing participant friendly engagement tools, they needed next-generation sequencing technology that could produce clinical-grade data at scale. Historically, this would have required coordinating with multiple partners.

About Renown IHI

More details

About Renown IHI

Renown Institute for Health Innovation (Renown IHI) is a collaboration between Renown Health – a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute – a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing plane.

About the Healthy Nevada Project

More details

About the Healthy Nevada Project

The Healthy Nevada Project is a population health study run by Renown IHI. The goal is to understand factors that determine health outcomes—one of which is genetics. They hope to learn about how your genetics impact your personal health trajectory and use this information to help you make better decisions about your health.

Helix services used

More details

Helix services used

  • One of the world’s largest CLIA-certified, CAP-accredited next-generation sequencing labs
  • Exome+®: a panel-grade medical exome enhanced by more than 300,000 informative non-coding regions
  • Co-branded ancestry + traits DNA product for all participants
  • Secure storage of genomic data for the lifetime of the participant
  • Infrastructure and data to facilitate research
  • In-house clinical and scientific expertise

The solution

Combining Renown IHI’s expertise in healthcare and research with Helix’s end-to-end population 
health solution.

Renown IHI worked closely with Helix to customize its end-to-end population health solution. Helix's participant-facing engagement tools, in-house clinical and scientific expertise, clinical-grade Exome+® assay, and next-generation sequencing lab (one of the world's largest) provided this project with powerful tools that helped it become one of the fastest growing population sequencing initiatives in the United States.

More than an exome

Each participant’s DNA was sequenced using the Exome+® assay—far surpassing the amount of data collected in other comparable initiatives—enabling Renown IHI to deliver actionable insights to their patients and to be a leading innovator in precision health. Additionally, the Exome+ assay covers the entire exome plus more than 300,000 informative non-coding regions that are available to help participants (and their physicians) continue learning from their DNA over time.

Helix's end-to-end solution is powering one of the fastest growing population genomics initiatives in the United States

sequencing lab

Exome+ assay

engagement tools

Sequence once,
query often model

The results

In less than one year, Renown IHI has assembled one of the largest genomic and health data sets in the world and changed the standard of care in their community.



Sign-ups in the first four days


People recruited, sequenced, and given results in less than 6 months


Participants targeted in expansion plan


1 in 75

received actionable medical results across 3 conditions:

Familial hypercholesterolemia

Lynch Syndrome

Hereditary breast and ovarian cancer syndrome


would have been missed under current medical practice


had already developed indications of disease



Get in touch

To learn more about implementing a population genomics program, complete this form and we’ll be in touch soon.
If you have questions about your COVID-19 test result, please email


This could be the beginning of something big. A member 
of our team will send you a welcome email soon.

*Required fields


  1. Grzymski JJ, et al. Population genetic screening efficiently identifies carriers of autosomal dominant diseases. Nature Medicine.

    July. 27, 2020;

  2. Cirulli E.T. Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts.

    Nature Communications. Jan. 28, 2020;